Amit Chaudhary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amit Chaudhary has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Singh Panwar
Department of Metallurgical Engineering & Materials Science, Indian Institute of Technology Bombay, India
2 shared publications Monu Kaushik
Department of Industrial and Management Engineering, Indian Institute of Technology Kanpur, Uttar Pradesh, Kanpur, India
2 shared publicationsPrashant Singh
Department of Biotechnology, Indian Institute of Technology Hyderabad, Sangareddy, Telangana, India
2 shared publicationsSonu Pahal
University of Arkansas for Medical Sciences, University of Arkansas at Little Rock, Little Rock, AR, USA
2 shared publicationsVishvender Pahal
All Institute of Medical Sciences, Raebareli, 229405, India
2 shared publicationsAnup K. Prasad
Department of Metallurgical Engineering and Materials Science
1 shared publication
Latest Publications
- 3 March 2026
- Published by Springer Nature in Cell and tissue research
- Vol. 403 (3)
Brain peptides in Alzheimer’s disease - pathophysiology and therapeutic advances
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and hallmark neuropathological features, including extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles formed by hyperphosphorylated tau. Peptides occupy a central position in AD pathobiology: pathogenic species such as Aβ oligomers and tau-derived fragments drive synaptic failure, mitochondrial dysfunction, and neuroinflammation, whereas several endogenous neuropeptides exert compensatory neuroprotective, trophic, or homeostatic effects. In parallel, advances in peptide chemistry and structural biology have enabled the design of aggregation inhibitors, receptor-selective neuropeptide analogues, and cell-penetrating or brain-targeted peptide conjugates that modulate key pathways, including proteostasis, insulin and incretin signaling, neurotrophic support, and microglial activation. This review integrates current evidence on how brain peptides contribute to AD pathophysiology, summarizes recent progress in peptide-based therapeutic strategies and delivery platforms, and critically examines the remaining barriers to clinical translation, including blood-brain barrier penetration, metabolic stability, off-target effects, and the need for biomarker-guided patient stratification. By highlighting both mechanistic insights and translational advances, the review article outlines how next-generation engineered peptide therapeutics, used alone or in combination with existing disease-modifying agents, may help reshape the future landscape of AD diagnosis, prevention, and treatment.
- 3 March 2026
- Published by Springer Nature in Cell and tissue research
- Vol. 403 (3)
Brain peptides in Alzheimer’s disease - pathophysiology and therapeutic advances
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and hallmark neuropathological features, including extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles formed by hyperphosphorylated tau. Peptides occupy a central position in AD pathobiology: pathogenic species such as Aβ oligomers and tau-derived fragments drive synaptic failure, mitochondrial dysfunction, and neuroinflammation, whereas several endogenous neuropeptides exert compensatory neuroprotective, trophic, or homeostatic effects. In parallel, advances in peptide chemistry and structural biology have enabled the design of aggregation inhibitors, receptor-selective neuropeptide analogues, and cell-penetrating or brain-targeted peptide conjugates that modulate key pathways, including proteostasis, insulin and incretin signaling, neurotrophic support, and microglial activation. This review integrates current evidence on how brain peptides contribute to AD pathophysiology, summarizes recent progress in peptide-based therapeutic strategies and delivery platforms, and critically examines the remaining barriers to clinical translation, including blood-brain barrier penetration, metabolic stability, off-target effects, and the need for biomarker-guided patient stratification. By highlighting both mechanistic insights and translational advances, the review article outlines how next-generation engineered peptide therapeutics, used alone or in combination with existing disease-modifying agents, may help reshape the future landscape of AD diagnosis, prevention, and treatment.
- 7 October 2025
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 41 (41) , 27670-27682
C-Terminal Amidation: Structural Insights into Enhanced Antimicrobial Peptide Efficacy and Amyloidogenesis
Post-translational modifications, such as C-terminal amidation, are energetically costly but critical for membrane-active antimicrobial peptides (AMPs). This study examined the impact of C-terminal amidation on uperin 3.5 (U3.5, an amyloid-forming AMP) interactions with POPE:DOPG (3:1) lipid bilayers using molecular simulations. Whereas monomeric U3.5-NH2 rapidly attached to the lipid bilayer surface, forming a stable α-helix, U3.5-OH exhibited weaker interactions. Simulations of U3.5 tetramers, derived from the amyloid cryoelectron microscopy structure, revealed that amidation enhanced peptide-bilayer and peptide-peptide interactions, initially stabilizing β-sheet structures and facilitating embedding into the bilayer. The β-sheet tetramer gradually dissociated into monomeric U3.5-NH2 peptides on the bilayer surface. Following dissociation, the monomers formed stable, amphipathic α-helices that were strongly embedded in the bilayer, consistent with a carpet-like antimicrobial mechanism. Enhanced peptide-lipid interactions resulted in lipid redistribution and changes to membrane curvature, potentially leading to membrane rupture. These findings highlight the role of U3.5-NH2 amyloid as a "carrier vehicle" for antimicrobial action at the bilayer interface, emphasizing the crucial function of C-terminal amidation in stabilizing peptide structure and promoting antimicrobial activity.
- 7 October 2025
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 41 (41) , 27670-27682
C-Terminal Amidation: Structural Insights into Enhanced Antimicrobial Peptide Efficacy and Amyloidogenesis
Post-translational modifications, such as C-terminal amidation, are energetically costly but critical for membrane-active antimicrobial peptides (AMPs). This study examined the impact of C-terminal amidation on uperin 3.5 (U3.5, an amyloid-forming AMP) interactions with POPE:DOPG (3:1) lipid bilayers using molecular simulations. Whereas monomeric U3.5-NH2 rapidly attached to the lipid bilayer surface, forming a stable α-helix, U3.5-OH exhibited weaker interactions. Simulations of U3.5 tetramers, derived from the amyloid cryoelectron microscopy structure, revealed that amidation enhanced peptide-bilayer and peptide-peptide interactions, initially stabilizing β-sheet structures and facilitating embedding into the bilayer. The β-sheet tetramer gradually dissociated into monomeric U3.5-NH2 peptides on the bilayer surface. Following dissociation, the monomers formed stable, amphipathic α-helices that were strongly embedded in the bilayer, consistent with a carpet-like antimicrobial mechanism. Enhanced peptide-lipid interactions resulted in lipid redistribution and changes to membrane curvature, potentially leading to membrane rupture. These findings highlight the role of U3.5-NH2 amyloid as a "carrier vehicle" for antimicrobial action at the bilayer interface, emphasizing the crucial function of C-terminal amidation in stabilizing peptide structure and promoting antimicrobial activity.
- 30 August 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (11) , 5607-5619
Role of Monoclonal Antibodies in Alzheimer’s Disease: Successes, Failures, and Future Directions
Alzheimer’s disease (AD), referred to as a type of dementia, is a progressive neurodegenerative disease with cognitive decline and key features comprising extracellular amyloid-β(Aβ) and intracellular neurofibrillary tangles. Monoclonal antibodies (mAbs) are a new therapeutic approach targeting the specific biochemical abnormalities associated with AD. This review summarizes several mAbs designed for AD, which helps to describe their mechanisms, including amyloid clearance from the brain as well as regulation of neuroinflammation. Moreover, the data on mAbs-related publications are shown in terms of their annual growth rate. A series of clinical studies, from discovery to application, suggest that mAbs could revolutionize the course of AD. While current mAbs have shown promise, future directions focus on improving efficacy, reducing adverse effects, and expanding accessibility.
- 30 August 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (11) , 5607-5619
Role of Monoclonal Antibodies in Alzheimer’s Disease: Successes, Failures, and Future Directions
Alzheimer’s disease (AD), referred to as a type of dementia, is a progressive neurodegenerative disease with cognitive decline and key features comprising extracellular amyloid-β(Aβ) and intracellular neurofibrillary tangles. Monoclonal antibodies (mAbs) are a new therapeutic approach targeting the specific biochemical abnormalities associated with AD. This review summarizes several mAbs designed for AD, which helps to describe their mechanisms, including amyloid clearance from the brain as well as regulation of neuroinflammation. Moreover, the data on mAbs-related publications are shown in terms of their annual growth rate. A series of clinical studies, from discovery to application, suggest that mAbs could revolutionize the course of AD. While current mAbs have shown promise, future directions focus on improving efficacy, reducing adverse effects, and expanding accessibility.
- 23 August 2025
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 26 (9) , 5740-5752
Intrinsically Disordered to Stable and Reversible α-Helical Conformational Transition of α-Synuclein in a Neat Polymer Surfactant Mesophase
α-synuclein (α-Syn), an intrinsically disordered protein associated with Parkinson's disease, exhibits a high propensity for aggregation under physiological and in vitro conditions, even at low concentrations. This necessitates its storage in the lyophilized form at ≤ -20 °C. In this work, we demonstrate that dispersing native α-Syn in an aqueous solution of poly(ethylene glycol)(PEG)-based polymer surfactant (PS), followed by lyophilization, forms a viscoelastic material at room temperature, in which α-Syn adopts a highly stable and reversible α-helical secondary structure. Solid-state NMR analysis reveals that helix formation involves alanine, threonine, and valine residues, predominantly within the N-terminal and NAC regions. Interestingly, small-angle X-ray scattering (SAXS) studies indicate that a neat PS matrix exhibits a distorted lamellar mesophase; however, it becomes ordered upon α-Syn incorporation. All-atom MD simulations show that PS hydrophobic domains self-assemble into "nematic-like" structures that selectively interact with the hydrophobic residues in α-Syn. These findings establish polymer-driven strategies for long-term storage and structure-function stabilization of various therapeutic proteins.
- 23 August 2025
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 26 (9) , 5740-5752
Intrinsically Disordered to Stable and Reversible α-Helical Conformational Transition of α-Synuclein in a Neat Polymer Surfactant Mesophase
α-synuclein (α-Syn), an intrinsically disordered protein associated with Parkinson's disease, exhibits a high propensity for aggregation under physiological and in vitro conditions, even at low concentrations. This necessitates its storage in the lyophilized form at ≤ -20 °C. In this work, we demonstrate that dispersing native α-Syn in an aqueous solution of poly(ethylene glycol)(PEG)-based polymer surfactant (PS), followed by lyophilization, forms a viscoelastic material at room temperature, in which α-Syn adopts a highly stable and reversible α-helical secondary structure. Solid-state NMR analysis reveals that helix formation involves alanine, threonine, and valine residues, predominantly within the N-terminal and NAC regions. Interestingly, small-angle X-ray scattering (SAXS) studies indicate that a neat PS matrix exhibits a distorted lamellar mesophase; however, it becomes ordered upon α-Syn incorporation. All-atom MD simulations show that PS hydrophobic domains self-assemble into "nematic-like" structures that selectively interact with the hydrophobic residues in α-Syn. These findings establish polymer-driven strategies for long-term storage and structure-function stabilization of various therapeutic proteins.
- 13 December 2024
- Published by Springer Nature in Journal of Biosciences
- Vol. 50 (1) , 1-11
From data to discovery: Neuroinformatics in understanding Alzheimer's disease
Neuroinformatics, an interdisciplinary field integrating neuroscience and informatics, plays a crucial role in understanding the complexities of the brain and neurological diseases such as Alzheimer’s disease (AD). This review explores the applications, databases, and tools used in neuroinformatics, focusing on their role in AD research. Neuroinformatics facilitates data integration, analysis, and modeling, enabling researchers to unravel the underlying mechanisms of AD pathology. Various databases and tools provide access to neuroimaging, and genetic and clinical data, facilitating collaborative research and the development of diagnostic and therapeutic strategies. Neuroinformatics holds promise in advancing our understanding and treatment of AD, offering insights into disease progression, biomarker identification, and personalized medicine approaches.
- 13 December 2024
- Published by Springer Nature in Journal of Biosciences
- Vol. 50 (1) , 1-11
From data to discovery: Neuroinformatics in understanding Alzheimer's disease
Neuroinformatics, an interdisciplinary field integrating neuroscience and informatics, plays a crucial role in understanding the complexities of the brain and neurological diseases such as Alzheimer’s disease (AD). This review explores the applications, databases, and tools used in neuroinformatics, focusing on their role in AD research. Neuroinformatics facilitates data integration, analysis, and modeling, enabling researchers to unravel the underlying mechanisms of AD pathology. Various databases and tools provide access to neuroimaging, and genetic and clinical data, facilitating collaborative research and the development of diagnostic and therapeutic strategies. Neuroinformatics holds promise in advancing our understanding and treatment of AD, offering insights into disease progression, biomarker identification, and personalized medicine approaches.
- Open Access
- 1 January 2024
- Published by Open Science Publishers LLP in Journal of Applied Biology & Biotechnology
Unlocking the mysteries of Alzheimer’s disease: Role of single-cell sequencing in uncovering microbial infections
Alzheimer’s disease (AD) is a neurodegenerative disorder that is characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. Despite decades of research, the underlying causes of AD remain poorly understood. However, recent evidence suggests that microbial infections may play a role in the development and progression of AD. With the advent of single-cell sequencing (SCS) technology, researchers now have a powerful tool to study the microbial communities in AD brains at high resolution. This review article focuses on the latest research on the role of SCS in investigating the relationship between microbial infections and AD. By enabling the identification and characterization of specific microbial species and their interactions with host cells in AD brains, SCS has provided new insights into the complex microbial landscape of AD. Furthermore, this technology has the potential to impact the diagnosis and treatment of AD by revealing new targets for therapeutic intervention. Finally, we also discussed about the challenges, limitations, ethical, and translational considerations of SCS technology, as well as future research directions in this area. The potential impact of SCS on understanding microbial infections in AD is significant, and it may lead to the development of new therapies and preventive measures for this devastating disease. In conclusion, this review highlights the important role that SCS plays in advancing our understanding of the complex microbial communities in AD and their potential involvement in disease pathogenesis.
- 1 January 2024
- Published by Open Science Publishers LLP in Journal of Applied Biology & Biotechnology
Open AccessUnlocking the mysteries of Alzheimer’s disease: Role of single-cell sequencing in uncovering microbial infections
Alzheimer’s disease (AD) is a neurodegenerative disorder that is characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. Despite decades of research, the underlying causes of AD remain poorly understood. However, recent evidence suggests that microbial infections may play a role in the development and progression of AD. With the advent of single-cell sequencing (SCS) technology, researchers now have a powerful tool to study the microbial communities in AD brains at high resolution. This review article focuses on the latest research on the role of SCS in investigating the relationship between microbial infections and AD. By enabling the identification and characterization of specific microbial species and their interactions with host cells in AD brains, SCS has provided new insights into the complex microbial landscape of AD. Furthermore, this technology has the potential to impact the diagnosis and treatment of AD by revealing new targets for therapeutic intervention. Finally, we also discussed about the challenges, limitations, ethical, and translational considerations of SCS technology, as well as future research directions in this area. The potential impact of SCS on understanding microbial infections in AD is significant, and it may lead to the development of new therapies and preventive measures for this devastating disease. In conclusion, this review highlights the important role that SCS plays in advancing our understanding of the complex microbial communities in AD and their potential involvement in disease pathogenesis.
- 1 October 2022
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 19 (10) , 877-887
Screening of Natural Compounds Against SOD1 as a Therapeutic Target for Amyotrophic Lateral Sclerosis
Background: Amyotrophic lateral sclerosis (ALS) is an uncommon and progressive neurological illness that predominantly includes the neurons liable for voluntary muscular activities. Starting from weakness or stiffness in muscles, this gradually exploits the strength and ability to speak, eat, move, and even breathe. Its exact mechanism is still not clear, but mutations in the SOD1 gene have been reported to cause ALS, and some studies also found involvement of SOD1 overexpression in the pathogenesis of ALS. As of now, there is no remedy available for its cure. Objective: The objective of this study is to identify the potential inhibitors for wild type 1HL5, l113T mutant, and A4V mutant of SOD1 (Superoxide Dismutase 1) protein. Methods: In this study, in silico approaches like virtual screening, molecular docking, pharmacokinetic parameters study, and molecular dynamics simulation were used to identify the best potential inhibitors against wild type and mutant SOD1 protein. Results: On the basis of binding affinity and binding energy, the top three compounds ZINC000095486263, ZINC000095485989, and ZINC000028462577 were observed as the best compounds. In the case of 1HL5, ZINC000095486263 had the highest binding affinity with docking score - 10.62 Kcal/mol, 1UXM with ZINC000095485989 had the highest docking score -12.03 Kcal/mol, and 4A7V with ZINC000028462577 was found -11.72 Kcal/mol. Further, Molecular Dynamic Simulations (MDS) results showed that the ZINC000095486263, ZINC000095485989, and ZINC000095485956 compounds were formed a stable complex with 1HL5, 1UXM, and 4A7V respectively. Conclusions: After analyzing the results, we hereby conclude that natural compounds such as ZINC000095486263, ZINC000095485989, and ZINC000095485956 could be used as a potential inhibitor of 1HL5, 1UXM, and 4A7V respectively for ALS treatment and could be used as a drug. Further, In vivo/vitro study of these compounds could be a future direction in the field of drug discovery.
- 1 October 2022
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 19 (10) , 877-887
Screening of Natural Compounds Against SOD1 as a Therapeutic Target for Amyotrophic Lateral Sclerosis
Background: Amyotrophic lateral sclerosis (ALS) is an uncommon and progressive neurological illness that predominantly includes the neurons liable for voluntary muscular activities. Starting from weakness or stiffness in muscles, this gradually exploits the strength and ability to speak, eat, move, and even breathe. Its exact mechanism is still not clear, but mutations in the SOD1 gene have been reported to cause ALS, and some studies also found involvement of SOD1 overexpression in the pathogenesis of ALS. As of now, there is no remedy available for its cure. Objective: The objective of this study is to identify the potential inhibitors for wild type 1HL5, l113T mutant, and A4V mutant of SOD1 (Superoxide Dismutase 1) protein. Methods: In this study, in silico approaches like virtual screening, molecular docking, pharmacokinetic parameters study, and molecular dynamics simulation were used to identify the best potential inhibitors against wild type and mutant SOD1 protein. Results: On the basis of binding affinity and binding energy, the top three compounds ZINC000095486263, ZINC000095485989, and ZINC000028462577 were observed as the best compounds. In the case of 1HL5, ZINC000095486263 had the highest binding affinity with docking score - 10.62 Kcal/mol, 1UXM with ZINC000095485989 had the highest docking score -12.03 Kcal/mol, and 4A7V with ZINC000028462577 was found -11.72 Kcal/mol. Further, Molecular Dynamic Simulations (MDS) results showed that the ZINC000095486263, ZINC000095485989, and ZINC000095485956 compounds were formed a stable complex with 1HL5, 1UXM, and 4A7V respectively. Conclusions: After analyzing the results, we hereby conclude that natural compounds such as ZINC000095486263, ZINC000095485989, and ZINC000095485956 could be used as a potential inhibitor of 1HL5, 1UXM, and 4A7V respectively for ALS treatment and could be used as a drug. Further, In vivo/vitro study of these compounds could be a future direction in the field of drug discovery.
- Open Access
- 10 June 2018
- Published by Excellent Publishers in International Journal of Current Microbiology and Applied Sciences
- Vol. 7 (06) , 1821-1826
Evaluation of Genetic Divergence for Grain Yield and Its Contributing Traits in Field pea (Pisum sativum L. var. arvense)
International Journal of Current Microbiology and Applied Sciences ISSN:2319-7692(Print), ISSN:2319-7706(Online) is a multidisciplinary peer-reviewed journal with reputable academics and experts as members of its Editorial Board. The Current Microbiology aims to publish all the latest and outstanding research articles. Review and letters in all areas of major importance to techniques of microbiology and applied research with publishes high quality of review and research articles on novel aspects of Microbiology including Environmental, Food, Agricultural, Medical, Pharmaceutical, Veterinary, Soil, Water and Biodeterioration.
- 10 June 2018
- Published by Excellent Publishers in International Journal of Current Microbiology and Applied Sciences
- Vol. 7 (06) , 1821-1826
Open AccessEvaluation of Genetic Divergence for Grain Yield and Its Contributing Traits in Field pea (Pisum sativum L. var. arvense)
International Journal of Current Microbiology and Applied Sciences ISSN:2319-7692(Print), ISSN:2319-7706(Online) is a multidisciplinary peer-reviewed journal with reputable academics and experts as members of its Editorial Board. The Current Microbiology aims to publish all the latest and outstanding research articles. Review and letters in all areas of major importance to techniques of microbiology and applied research with publishes high quality of review and research articles on novel aspects of Microbiology including Environmental, Food, Agricultural, Medical, Pharmaceutical, Veterinary, Soil, Water and Biodeterioration.
- Open Access
- 1 April 2013
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 12 (4) , 416-426
A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface
Monoclonal antibodies against mesothelin are being evaluated for the treatment of mesothelioma and multiple forms of cancers, and show great promise for clinical development for solid cancers. Antibodies against mesothelin have been shown to act via immunotoxin-based inhibition of tumor growth and induction of antibody-dependent cell-mediated cytotoxicity (ADCC). However, complement-dependent cytotoxicity (CDC), considered an important additional mechanism of therapeutic antibodies against tumors, is inactive for such antibodies. Here, we used phage display antibody engineering technology and synthetic peptide screening to identify SD1, a human single-domain antibody to mesothelin. SD1 recognizes a conformational epitope at the C-terminal end (residues 539–588) of mesothelin close to the cell surface. To investigate SD1 as a potential therapeutic agent, we generated a recombinant human Fc (SD1-hFc) fusion protein. Interestingly, the SD1-hFc protein exhibits strong CDC activity, in addition to ADCC, against mesothelin-expressing tumor cells. Furthermore, it causes growth inhibition of human tumor xenografts in nude mice as a single agent. SD1 is the first human single-domain antibody targeting mesothelin-expressing tumors, shows potential as a cancer therapeutic candidate, and may improve current antibody therapy targeting mesothelin-expressing tumors. Mol Cancer Ther; 12(4); 416–26. ©2013 AACR.
- 1 April 2013
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 12 (4) , 416-426
Open AccessA Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface
Monoclonal antibodies against mesothelin are being evaluated for the treatment of mesothelioma and multiple forms of cancers, and show great promise for clinical development for solid cancers. Antibodies against mesothelin have been shown to act via immunotoxin-based inhibition of tumor growth and induction of antibody-dependent cell-mediated cytotoxicity (ADCC). However, complement-dependent cytotoxicity (CDC), considered an important additional mechanism of therapeutic antibodies against tumors, is inactive for such antibodies. Here, we used phage display antibody engineering technology and synthetic peptide screening to identify SD1, a human single-domain antibody to mesothelin. SD1 recognizes a conformational epitope at the C-terminal end (residues 539–588) of mesothelin close to the cell surface. To investigate SD1 as a potential therapeutic agent, we generated a recombinant human Fc (SD1-hFc) fusion protein. Interestingly, the SD1-hFc protein exhibits strong CDC activity, in addition to ADCC, against mesothelin-expressing tumor cells. Furthermore, it causes growth inhibition of human tumor xenografts in nude mice as a single agent. SD1 is the first human single-domain antibody targeting mesothelin-expressing tumors, shows potential as a cancer therapeutic candidate, and may improve current antibody therapy targeting mesothelin-expressing tumors. Mol Cancer Ther; 12(4); 416–26. ©2013 AACR.
- Open Access
- 1 January 2006
- Published by Medknow in Journal of Carcinogenesis
- Vol. 5 (1) , 18
Invasive aspergillosis causing small bowel infarction in a patient of carcinoma breast undergoing chemotherapy.
To report a 45 year old lady presenting with proximal jejunal gangrene due to invasive Aspergillosis. The patient was undergoing adjuvant chemotherapy for advance carcinoma of breast (Stage IV). The patient was referred to our surgical emergency for acute abdominal symptoms for 6 hours. Histopathology revealed bowel wall necrosis and vascular invasion by Aspergillus Fumigatus. Postoperative recovery was uneventful and the patient received Amphotericin-B (1 mg/kg/day) for invasive aspergillosis. Invasive pulmonary aspergillosis was confirmed by isolating Aspergillus Fumigatus from bronchoalveolar lavage and by a positive circulating galactomannan test (ELISA Assay). Detailed history revealed dry cough and two episodes of haemoptesis for 2 weeks. Haemogram and counts revealed anemia and neutropenia. Plain X-ray of the abdomen showed multiple air fluid levels and ultrasound of the abdomen revealed distended bowel loops. On exploration small bowel was found to be gangrenous. The patient was successfully managed by supportive treatment and conventional intravenous Amphotericin-B for 2 weeks. The lady was discharged one week after completion of antifungal therapy and one month later she underwent toilet mastectomy. The lady came to follow up for 1 year and she is currently under hormone therapy. With the emergence of new and powerful immunosuppressive, anticancer drugs and potent antibiotics the survival of transplant and critically ill patients has remarkably increased but it has shown a significant rise in the incidence of invasive opportunistic fungal infections. We conclude hat the diagnosis of invasive gastrointestinal aspergillosis may be considered in a neutropenic patient with acute abdominal symptoms.
- 1 January 2006
- Published by Medknow in Journal of Carcinogenesis
- Vol. 5 (1) , 18
Open AccessInvasive aspergillosis causing small bowel infarction in a patient of carcinoma breast undergoing chemotherapy.
To report a 45 year old lady presenting with proximal jejunal gangrene due to invasive Aspergillosis. The patient was undergoing adjuvant chemotherapy for advance carcinoma of breast (Stage IV). The patient was referred to our surgical emergency for acute abdominal symptoms for 6 hours. Histopathology revealed bowel wall necrosis and vascular invasion by Aspergillus Fumigatus. Postoperative recovery was uneventful and the patient received Amphotericin-B (1 mg/kg/day) for invasive aspergillosis. Invasive pulmonary aspergillosis was confirmed by isolating Aspergillus Fumigatus from bronchoalveolar lavage and by a positive circulating galactomannan test (ELISA Assay). Detailed history revealed dry cough and two episodes of haemoptesis for 2 weeks. Haemogram and counts revealed anemia and neutropenia. Plain X-ray of the abdomen showed multiple air fluid levels and ultrasound of the abdomen revealed distended bowel loops. On exploration small bowel was found to be gangrenous. The patient was successfully managed by supportive treatment and conventional intravenous Amphotericin-B for 2 weeks. The lady was discharged one week after completion of antifungal therapy and one month later she underwent toilet mastectomy. The lady came to follow up for 1 year and she is currently under hormone therapy. With the emergence of new and powerful immunosuppressive, anticancer drugs and potent antibiotics the survival of transplant and critically ill patients has remarkably increased but it has shown a significant rise in the incidence of invasive opportunistic fungal infections. We conclude hat the diagnosis of invasive gastrointestinal aspergillosis may be considered in a neutropenic patient with acute abdominal symptoms.